Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Stomach Neoplasms 1Resectable Pancreatic Cancer 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Esophageal 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Advanced and/or Metastatic Solid Tumours 1Advanced Esophageal 1Adenocarcinoma 1

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioma × nimotuzumab × Clear all
NCT03388372 2018-01-03

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
39 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡